Loading…

Resistance-Modifying Agents. 11. Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure−Activity Relationships for Nucleoside Transport Inhibition and Binding to α1-Acid Glycoprotein

The cardiovascular and antithrombotic agent dipyridamole (DP) has potential therapeutic utility as a modulator of the activity of antimetabolite antitumor agents by virtue of its inhibition of nucleoside transport. However, the activity of DP can be compromised by binding to the acute phase serum pr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2004-09, Vol.47 (20), p.4905-4922
Main Authors: Curtin, Nicola J, Barlow, Hannah C, Bowman, Karen J, Calvert, A. Hilary, Davison, Richard, Golding, Bernard T, Huang, Bing, Loughlin, Peter J, Newell, David R, Smith, Peter G, Griffin, Roger J
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 4922
container_issue 20
container_start_page 4905
container_title Journal of medicinal chemistry
container_volume 47
creator Curtin, Nicola J
Barlow, Hannah C
Bowman, Karen J
Calvert, A. Hilary
Davison, Richard
Golding, Bernard T
Huang, Bing
Loughlin, Peter J
Newell, David R
Smith, Peter G
Griffin, Roger J
description The cardiovascular and antithrombotic agent dipyridamole (DP) has potential therapeutic utility as a modulator of the activity of antimetabolite antitumor agents by virtue of its inhibition of nucleoside transport. However, the activity of DP can be compromised by binding to the acute phase serum protein, α1-acid glycoprotein (AGP). Analogues of DP were synthesized and evaluated as inhibitors of 3H-thymidine uptake into L1210 leukamia cells in the presence and absence of 5 mg/mL AGP. Compounds with potency similar to that of DP were identified where the piperidino substituents at the 4,8-positions were replaced by 4‘-methoxybenzylamino, 3‘,4‘-dimethoxybenzylamino, or piperonylamino groups. Replacement of the diethanolamino groups at the 2,6-positions of DP by alkylamino or alkoxy substituents was tolerated, although at least one oxygen-bearing function (hydroxyl or alkoxy) was required in the side chain for activity comparable to that of DP. Whereas AGP completely ablated the activity of DP, the majority of the newer compounds synthesized retained significant activity in the presence of excess AGP, although replacement of the piperidino groups at the 4,8-positions by N-methylbenzylamino substituents did, in some cases, restore susceptibility to AGP. Selected compounds have been demonstrated to prevent rescue from antifolate cytotoxicity, mediated by nucleoside salvage.
doi_str_mv 10.1021/jm040772w
format article
fullrecord <record><control><sourceid>istex_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_16142157</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_TPS_KV1857CF_7</sourcerecordid><originalsourceid>FETCH-LOGICAL-a166t-4889b1576f5595aedf3c901d0aaba0a24c1118c49314dc343f5f170b257e7a53</originalsourceid><addsrcrecordid>eNpFkcFuEzEQhi0EEqFw4A184cYGj71eJ8cQ2lJRoGoiLghZju1tHDb2yvYC-waceRNehBfgxpPgECgna-RP38z8g9BjIFMgFJ7t9qQmQtDPd9AEOCVVPSP1XTQhhNKKNpTdRw9S2hFCGFA2QT-vbXIpK69t9ToY147O3-DFjfU5TTHAFF-N0e2dCe_507oyH_pj6bzFhR86lUNMOLR44bPLwz5E_CIORaGz--TyOMWr0eftoQtW3uBVjoPOQ7S_vn77x-BrWzwu-LR1fcJtcbwZdGdDcsbidVQ-9SFmfOG3buMO4B_Vc-fNYdoc8I_vUC20M_i8G3XoY8jW-YfoXqu6ZB_9fU_Q-ux0vXxZXb49v1guLisFTZNLQrP5BrhoWs7nXFnTMj0nYIhSG0UUrTUAzHQ9Z1AbzWrW8hYE2VAurFCcnaAnR22vklZdW8bVLsm-5KTiKKGBmhZ94aojV_K2X27_VfwoG8EEl-urlXz1DmZcLM-k-O9VOsldGKIvS0gg8nBoeXto9hu8KaBQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Resistance-Modifying Agents. 11. Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure−Activity Relationships for Nucleoside Transport Inhibition and Binding to α1-Acid Glycoprotein</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Curtin, Nicola J ; Barlow, Hannah C ; Bowman, Karen J ; Calvert, A. Hilary ; Davison, Richard ; Golding, Bernard T ; Huang, Bing ; Loughlin, Peter J ; Newell, David R ; Smith, Peter G ; Griffin, Roger J</creator><creatorcontrib>Curtin, Nicola J ; Barlow, Hannah C ; Bowman, Karen J ; Calvert, A. Hilary ; Davison, Richard ; Golding, Bernard T ; Huang, Bing ; Loughlin, Peter J ; Newell, David R ; Smith, Peter G ; Griffin, Roger J</creatorcontrib><description>The cardiovascular and antithrombotic agent dipyridamole (DP) has potential therapeutic utility as a modulator of the activity of antimetabolite antitumor agents by virtue of its inhibition of nucleoside transport. However, the activity of DP can be compromised by binding to the acute phase serum protein, α1-acid glycoprotein (AGP). Analogues of DP were synthesized and evaluated as inhibitors of 3H-thymidine uptake into L1210 leukamia cells in the presence and absence of 5 mg/mL AGP. Compounds with potency similar to that of DP were identified where the piperidino substituents at the 4,8-positions were replaced by 4‘-methoxybenzylamino, 3‘,4‘-dimethoxybenzylamino, or piperonylamino groups. Replacement of the diethanolamino groups at the 2,6-positions of DP by alkylamino or alkoxy substituents was tolerated, although at least one oxygen-bearing function (hydroxyl or alkoxy) was required in the side chain for activity comparable to that of DP. Whereas AGP completely ablated the activity of DP, the majority of the newer compounds synthesized retained significant activity in the presence of excess AGP, although replacement of the piperidino groups at the 4,8-positions by N-methylbenzylamino substituents did, in some cases, restore susceptibility to AGP. Selected compounds have been demonstrated to prevent rescue from antifolate cytotoxicity, mediated by nucleoside salvage.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm040772w</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; General aspects ; Medical sciences ; Miscellaneous ; Pharmacology. Drug treatments</subject><ispartof>Journal of medicinal chemistry, 2004-09, Vol.47 (20), p.4905-4922</ispartof><rights>Copyright © 2004 American Chemical Society</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16142157$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Curtin, Nicola J</creatorcontrib><creatorcontrib>Barlow, Hannah C</creatorcontrib><creatorcontrib>Bowman, Karen J</creatorcontrib><creatorcontrib>Calvert, A. Hilary</creatorcontrib><creatorcontrib>Davison, Richard</creatorcontrib><creatorcontrib>Golding, Bernard T</creatorcontrib><creatorcontrib>Huang, Bing</creatorcontrib><creatorcontrib>Loughlin, Peter J</creatorcontrib><creatorcontrib>Newell, David R</creatorcontrib><creatorcontrib>Smith, Peter G</creatorcontrib><creatorcontrib>Griffin, Roger J</creatorcontrib><title>Resistance-Modifying Agents. 11. Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure−Activity Relationships for Nucleoside Transport Inhibition and Binding to α1-Acid Glycoprotein</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The cardiovascular and antithrombotic agent dipyridamole (DP) has potential therapeutic utility as a modulator of the activity of antimetabolite antitumor agents by virtue of its inhibition of nucleoside transport. However, the activity of DP can be compromised by binding to the acute phase serum protein, α1-acid glycoprotein (AGP). Analogues of DP were synthesized and evaluated as inhibitors of 3H-thymidine uptake into L1210 leukamia cells in the presence and absence of 5 mg/mL AGP. Compounds with potency similar to that of DP were identified where the piperidino substituents at the 4,8-positions were replaced by 4‘-methoxybenzylamino, 3‘,4‘-dimethoxybenzylamino, or piperonylamino groups. Replacement of the diethanolamino groups at the 2,6-positions of DP by alkylamino or alkoxy substituents was tolerated, although at least one oxygen-bearing function (hydroxyl or alkoxy) was required in the side chain for activity comparable to that of DP. Whereas AGP completely ablated the activity of DP, the majority of the newer compounds synthesized retained significant activity in the presence of excess AGP, although replacement of the piperidino groups at the 4,8-positions by N-methylbenzylamino substituents did, in some cases, restore susceptibility to AGP. Selected compounds have been demonstrated to prevent rescue from antifolate cytotoxicity, mediated by nucleoside salvage.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>General aspects</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Pharmacology. Drug treatments</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpFkcFuEzEQhi0EEqFw4A184cYGj71eJ8cQ2lJRoGoiLghZju1tHDb2yvYC-waceRNehBfgxpPgECgna-RP38z8g9BjIFMgFJ7t9qQmQtDPd9AEOCVVPSP1XTQhhNKKNpTdRw9S2hFCGFA2QT-vbXIpK69t9ToY147O3-DFjfU5TTHAFF-N0e2dCe_507oyH_pj6bzFhR86lUNMOLR44bPLwz5E_CIORaGz--TyOMWr0eftoQtW3uBVjoPOQ7S_vn77x-BrWzwu-LR1fcJtcbwZdGdDcsbidVQ-9SFmfOG3buMO4B_Vc-fNYdoc8I_vUC20M_i8G3XoY8jW-YfoXqu6ZB_9fU_Q-ux0vXxZXb49v1guLisFTZNLQrP5BrhoWs7nXFnTMj0nYIhSG0UUrTUAzHQ9Z1AbzWrW8hYE2VAurFCcnaAnR22vklZdW8bVLsm-5KTiKKGBmhZ94aojV_K2X27_VfwoG8EEl-urlXz1DmZcLM-k-O9VOsldGKIvS0gg8nBoeXto9hu8KaBQ</recordid><startdate>20040923</startdate><enddate>20040923</enddate><creator>Curtin, Nicola J</creator><creator>Barlow, Hannah C</creator><creator>Bowman, Karen J</creator><creator>Calvert, A. Hilary</creator><creator>Davison, Richard</creator><creator>Golding, Bernard T</creator><creator>Huang, Bing</creator><creator>Loughlin, Peter J</creator><creator>Newell, David R</creator><creator>Smith, Peter G</creator><creator>Griffin, Roger J</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope></search><sort><creationdate>20040923</creationdate><title>Resistance-Modifying Agents. 11. Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure−Activity Relationships for Nucleoside Transport Inhibition and Binding to α1-Acid Glycoprotein</title><author>Curtin, Nicola J ; Barlow, Hannah C ; Bowman, Karen J ; Calvert, A. Hilary ; Davison, Richard ; Golding, Bernard T ; Huang, Bing ; Loughlin, Peter J ; Newell, David R ; Smith, Peter G ; Griffin, Roger J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a166t-4889b1576f5595aedf3c901d0aaba0a24c1118c49314dc343f5f170b257e7a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>General aspects</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Curtin, Nicola J</creatorcontrib><creatorcontrib>Barlow, Hannah C</creatorcontrib><creatorcontrib>Bowman, Karen J</creatorcontrib><creatorcontrib>Calvert, A. Hilary</creatorcontrib><creatorcontrib>Davison, Richard</creatorcontrib><creatorcontrib>Golding, Bernard T</creatorcontrib><creatorcontrib>Huang, Bing</creatorcontrib><creatorcontrib>Loughlin, Peter J</creatorcontrib><creatorcontrib>Newell, David R</creatorcontrib><creatorcontrib>Smith, Peter G</creatorcontrib><creatorcontrib>Griffin, Roger J</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Curtin, Nicola J</au><au>Barlow, Hannah C</au><au>Bowman, Karen J</au><au>Calvert, A. Hilary</au><au>Davison, Richard</au><au>Golding, Bernard T</au><au>Huang, Bing</au><au>Loughlin, Peter J</au><au>Newell, David R</au><au>Smith, Peter G</au><au>Griffin, Roger J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resistance-Modifying Agents. 11. Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure−Activity Relationships for Nucleoside Transport Inhibition and Binding to α1-Acid Glycoprotein</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2004-09-23</date><risdate>2004</risdate><volume>47</volume><issue>20</issue><spage>4905</spage><epage>4922</epage><pages>4905-4922</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>The cardiovascular and antithrombotic agent dipyridamole (DP) has potential therapeutic utility as a modulator of the activity of antimetabolite antitumor agents by virtue of its inhibition of nucleoside transport. However, the activity of DP can be compromised by binding to the acute phase serum protein, α1-acid glycoprotein (AGP). Analogues of DP were synthesized and evaluated as inhibitors of 3H-thymidine uptake into L1210 leukamia cells in the presence and absence of 5 mg/mL AGP. Compounds with potency similar to that of DP were identified where the piperidino substituents at the 4,8-positions were replaced by 4‘-methoxybenzylamino, 3‘,4‘-dimethoxybenzylamino, or piperonylamino groups. Replacement of the diethanolamino groups at the 2,6-positions of DP by alkylamino or alkoxy substituents was tolerated, although at least one oxygen-bearing function (hydroxyl or alkoxy) was required in the side chain for activity comparable to that of DP. Whereas AGP completely ablated the activity of DP, the majority of the newer compounds synthesized retained significant activity in the presence of excess AGP, although replacement of the piperidino groups at the 4,8-positions by N-methylbenzylamino substituents did, in some cases, restore susceptibility to AGP. Selected compounds have been demonstrated to prevent rescue from antifolate cytotoxicity, mediated by nucleoside salvage.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><doi>10.1021/jm040772w</doi><tpages>18</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2004-09, Vol.47 (20), p.4905-4922
issn 0022-2623
1520-4804
language eng
recordid cdi_pascalfrancis_primary_16142157
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Antineoplastic agents
Biological and medical sciences
General aspects
Medical sciences
Miscellaneous
Pharmacology. Drug treatments
title Resistance-Modifying Agents. 11. Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure−Activity Relationships for Nucleoside Transport Inhibition and Binding to α1-Acid Glycoprotein
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A25%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resistance-Modifying%20Agents.%2011.%20Pyrimido%5B5,4-d%5Dpyrimidine%20Modulators%20of%20Antitumor%20Drug%20Activity.%20Synthesis%20and%20Structure%E2%88%92Activity%20Relationships%20for%20Nucleoside%20Transport%20Inhibition%20and%20Binding%20to%20%CE%B11-Acid%20Glycoprotein&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Curtin,%20Nicola%20J&rft.date=2004-09-23&rft.volume=47&rft.issue=20&rft.spage=4905&rft.epage=4922&rft.pages=4905-4922&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm040772w&rft_dat=%3Cistex_pasca%3Eark_67375_TPS_KV1857CF_7%3C/istex_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a166t-4889b1576f5595aedf3c901d0aaba0a24c1118c49314dc343f5f170b257e7a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true